MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

Abstract Background The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient survival. MAP17 (PDZK1IP1) is a small m...

Full description

Bibliographic Details
Main Authors: Irene Ferrer, Álvaro Quintanal-Villalonga, Sonia Molina-Pinelo, Jose Manuel Garcia-Heredia, Marco Perez, Rocío Suárez, Santiago Ponce-Aix, Luis Paz-Ares, Amancio Carnero
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Biomarkers
Lung cancer
PDZK1IP1
Treatment efficacy
Online Access:http://link.springer.com/article/10.1186/s13046-018-0871-7

Internet

http://link.springer.com/article/10.1186/s13046-018-0871-7

Similar Items